Express News | Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"

BenzingaDec 12 15:58 ET

Bears Are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now

Zacks Dec 9 09:05 ET

Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital

Dow JonesDec 5 07:16 ET · Ratings

Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital

Dow JonesDec 5 07:16 ET · Ratings

Can-Fite BioPharma Reports 8-Year Survival With Namodenoson in Liver Cancer Patient and Announces Phase III Study Enrollment

Quiver QuantitativeDec 4 07:12 ET

8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite's Namodenoson Drug

GlobeNewswireDec 4 07:00 ET